Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:01 ET
|
Coherus BioSciences, Inc.
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million...
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
May 09, 2024 07:30 ET
|
Coherus BioSciences, Inc.
– New $38.7 million term loan with a May 2029 maturity –– $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® – REDWOOD CITY, Calif., May 09, 2024 (GLOBE...
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
May 08, 2024 09:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study...
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
May 01, 2024 16:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market...
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:02 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective...
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
April 08, 2024 08:30 ET
|
Coherus BioSciences, Inc.
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion ––...
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
March 13, 2024 16:01 ET
|
Coherus BioSciences, Inc.
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net...
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
March 05, 2024 16:01 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be...
Coherus Completes Divestiture of Ophthalmology Franchise
March 04, 2024 01:00 ET
|
Coherus BioSciences, Inc.
– Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology – REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) --...
Coherus BioSciences Announces New Employment Inducement Grants
February 23, 2024 17:33 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation...